Neurotrophin 3 promotes purification and proliferation of olfactory ensheathing cells from human nose.
Several studies have demonstrated the potential of olfactory ensheathing cells for the repair of central and peripheral nerve injury. However, the majority of these studies have been performed with olfactory ensheathing cells derived from the olfactory bulbs, situated inside the skull. A more clinically relevant source of olfactory ensheathing cells is the olfactory mucosa, located in the nose. To be successful, an autologous transplant of nasal ensheathing glia would require a large number of purified cells. To address this issue, we have focused our research on three neurotrophic factors, namely nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin 3 (NT3). We show here that their respective receptors, TrkA, TrkB, TrkC, as well as p75(NTR) (the low affinity NGF receptor), are expressed in vitro by the nasal ensheathing cells; the three neurotrophins promote purification and proliferation of these glial cells, with an optimal concentration of 50 ng/ml; and human ensheathing cells can be easily biopsied and highly purified using a serum-free medium supplemented with NT3. This technique opens the door for clinical trials in which nasal ensheathing cells will be autotransplanted in humans suffering from nerve injury.
Bianco
John I
JI
Centre for Molecular Neurobiology, School of Biomolecular and Biomedical Science, Griffith University, Nathan, Queensland 4111, Australia. j.bianco@griffith.edu.au
Perry
Chris
C
Harkin
Damien G
DG
Mackay-Sim
Alan
A
Féron
François
F
D000328:Adult; D000368:Aged; D000818:Animals; D001706:Biopsy / Q000379:methods; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology / Q000627:therapeutic use; D018929:Cell Culture Techniques / Q000379:methods*; D002469:Cell Separation; D002478:Cells, Cultured; D016895:Culture Media, Serum-Free / Q000494:pharmacology; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D020932:Nerve Growth Factor / Q000494:pharmacology / Q000627:therapeutic use; D009416:Nerve Regeneration / Q000502:physiology; D009457:Neuroglia / Q000166:cytology / Q000187:drug effects* / Q000637:transplantation; D020933:Neurotrophin 3 / Q000494:pharmacology* / Q000627:therapeutic use; D009831:Olfactory Mucosa / Q000166:cytology*; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020800:Receptor, Nerve Growth Factor; D020917:Receptor, trkA / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D020813:Receptor, trkB / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D020812:Receptor, trkC / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D017475:Receptors, Nerve Growth Factor / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D009418:S100 Proteins / Q000378:metabolism; D014182:Transplantation, Autologous / Q000379:methods
D019208:Brain-Derived Neurotrophic Factor; D016895:Culture Media, Serum-Free; D005904:Glial Fibrillary Acidic Protein; D020933:Neurotrophin 3; D012333:RNA, Messenger; D020800:Receptor, Nerve Growth Factor; D017475:Receptors, Nerve Growth Factor; D009418:S100 Proteins; D020932:Nerve Growth Factor; D020917:Receptor, trkA; D020813:Receptor, trkB; D020812:Receptor, trkC